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Scalable Culturing of Primary 
Human Glioblastoma Tumor-
Initiating Cells with a Cell-Friendly 
Culture System
Qiang Li1,2, Haishuang Lin1, Jack Rauch1, Loic P. Deleyrolle3, Brent A. Reynolds3,  
Hendrik J. Viljoen1, Chi Zhang4, Chi Zhang5, Linxia Gu  6, Erika Van Wyk7 & Yuguo Lei  1,2,8,9
Glioblastoma is the most aggressive and deadly brain cancer. There is growing interest to develop 
drugs that specifically target to glioblastoma tumor-initiating cells (TICs). However, the cost-effective 
production of large numbers of high quality glioblastoma TICs for drug discovery with current 
cell culturing technologies remains very challenging. Here, we report a new method that cultures 
glioblastoma TICs in microscale alginate hydrogel tubes (or AlgTubes). The AlgTubes allowed long-term 
culturing (~50 days, 10 passages) of glioblastoma TICs with high growth rate (~700-fold expansion/14 
days), high cell viability and high volumetric yield (~3.0 × 108 cells/mL) without losing the stem cell 
properties, all offered large advancements over current culturing methods. This method can be applied 
for the scalable production of glioblastoma TICs at affordable cost for drug discovery.
Glioblastoma is the most aggressive and deadly adult brain cancer1–3. The standard treatments including surgery, 
chemotherapy and radiotherapy cannot cure the disease. The median survival time is about 15 months4. Studies 
attribute the high drug resistance and recurrence of glioblastoma to the existence of a small population of cells 
termed the tumor-initiating cells (TICs) within the tumor mass5–7. TICs have the stem cell properties including 
self-renewal and differentiation. They also have high resistance to the standard treatments8. The survived TICs 
expand and differentiate to re-initiate tumors, resulting in recurrence. Therefore, researchers have suggested that 
killing or differentiating these glioblastoma TICs represents a promising approach to treat or cure glioblastoma9.
Human glioblastoma TICs have been successfully isolated through neurosphere culturing or using surface 
markers such as CD1331,10, CD1511 and ABCG212,13, etc. Some recent studies showed that using these markers, 
such as CD133, to define glioblastoma TICs is still controversial11,14–16. The glioblastoma TICs also express Nestin, 
Sox2, CD44, or Olig22,17. These cells can be cultured for a long time and differentiated into astrocytes, neurons 
and oligodendrocytes in vitro1,2,7. When transplanted into immune deficiency mice, they can form tumors that are 
similar to the primary tumors found in the patients7,18. These TICs are very valuable for developing new drugs for 
treating glioblastoma. For instance, many studies have already applied these cultured TICs for drug discovery and 
development19–23. Drug discovery requires large numbers of cells. For example, it is estimated that ~1 × 1010 cells 
are needed to screen a one-million-compound library once20. Advances in combinatorial chemistry, noncoding 
RNAs and investigations of complex signaling and transcriptional networks have given rise to large libraries that 
can be screened20. Massive numbers of TICs are, therefore, needed to deliver on the biomedical promise of these 
cells.
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However, culturing high quantity and high quality glioblastoma TICs with current cell culturing methods 
including the two dimensional (2D) adherent culturing and three dimensional (3D) suspension culturing remains 
very challenging. Pollard et al. reported that glioblastoma TICs could be cultured on 2D surface for long-term 
with good cell viability, proliferation and maintenance of stem cell phenotypes2. A number of reports have shown 
that glioblastoma TICs could be cultured as aggregates (or neurospheres) with good maintenance of cell pheno-
type17,24–26. Although these culture systems work well for preparing cells for basic science research, they are con-
sidered not suitable for producing cells at large scales27. 2D culturing is labor-, space- and reagent-consuming28–30. 
Additionally, a 2D environment is very different from an in vivo environment. It can induce significant DNA 
instability and positively select cells gaining survival and growth privileges due to the genetic aberrations31–34. 
The neurosphere method usually cultures TICs at low density (e.g. <1 × 106 cells/mL)18, requiring large culture 
volume to generate cells at large-scale.
We here report a novel and scalable cell culture system to address this challenge. With this technology, TICs 
are suspended and cultured in microscale alginate hydrogel tubes (or AlgTubes) that are suspended in the cell 
culture medium in a culture vessel (Fig. 1A,B). We showed that, under optimized culture conditions, TICs from 
multiple patients could be cultured with high cell viability, growth rate (~700-fold expansion/14 days) and volu-
metric yield (~3.0 × 108 cells/mL), all offered large advancements over the current culturing methods. Alginate 
hydrogels are used for making this culture system because35 they: (1) can be quickly processed in large scales 
with the extruder; (2) can be easily dissolved to release the product; (3) allow quick nutrient diffusion through 
the hydrogel shell; (4) are mechanically and chemically stable for cell cultures; and (5) are transparent, allowing 
optical monitoring. Additionally, alginates are affordable and available in large quantities. They have no toxicity36. 
This technology can be applied for the mass production of glioblastoma TICs at affordable cost for drug discovery.
Results
The AlgTubes cell culture system. In vivo, glioblastoma TICs reside in 3D microenvironments that have 
plenty of cell-cell and cell-ECM (extracellular matrix) interactions, sufficient supply of nutrients, oxygen and 
growth factors and no or minimal hydrodynamic stresses37. We designed the AlgTubes to mimic these in vivo 
microenvironments for culturing glioblastoma TICs. The hydrogel tubes created cell-friendly microspaces that 
allowed TICs to interact with each other and expand. Meanwhile, the tubes protected TICs from hydrodynamic 
stresses in the culture vessel and confined the cell mass less than 400 µm (in radial diameter) to ensure efficient 
mass transport during the entire culture (Fig. 1A,B).
A custom-made micro-extruder was made to process glioblastoma AlgTubes (Fig. 1C). A 2% hyaluronic acid 
(HA) solution with single dissociated glioblastoma TICs was pumped into the central channel and a 1.5% alginate 
solution was pumped into the side channel of the extruder, respectively (Fig. 1C). The two solutions as coaxial 
core-shell flows were extruded into a 100 mM Ca2+ buffer, which instantly crosslinked the alginate flow to form 
hydrogel shells to make AlgTubes. In the AlgTubes, individual TICs associated with neighboring cells to form 
small cell clusters within 24 hours. Subsequently, these clusters grew and eventually merged to form fibrous cell 
masses (Fig. 1D). To passage cells, AlgTubes were dissolved with 0.5 mM ethylenediaminetetraacetic acid (EDTA) 
solution (5 mins at room temperature). The released cell masses were treated with 0.05% Trypsin for 10 minutes 
at 37 °C and dissociated into single cells for the following passage or analysis.
Culturing primary glioblastoma TICs in AlgTubes. To evaluate the general applicability, three 
patient-derived primary glioblastoma TICs (L0, L1 and L2) were cultured in the AlgTubes. These cells were estab-
lished as described in our previous publication7. They expressed neural stem cell markers including Nestin, SOX2 
and Olig2, while very few of them expressed the differentiation markers such as Tuj1 and GFAP (Fig. S1). They 
also expressed TIC markers mentioned in the literature such as CD133, CD15 and CD44. About 4.6%, 18.5% and 
99.8% of L0 cells were CD133+, CD15+ and CD44+, respectively. About 14.1%, 18.4% and 99.7% of L1 cells 
were CD133+, CD15+ and CD44+, respectively. And about 3.9%, 16.6% and 99.8% of L2 cells were CD133+, 
CD15+ and CD44+, respectively (Fig. S1). The results agree well with our previous publication7.
In AlgTubes, TICs expanded and formed fibrous cell masses with very few dead cells (Figs 2A,B, S2A,B). When seeded 
at 1 × 107 cells/mL, L0, L1 and L2 expanded ~36-, 34- and 28-fold, yielding 3.6 × 108, 3.4 × 108 and 2.8 × 108 cells/mL, 
respectively, by day 7 (Fig. 2C,D). Cells could be seeded at lower densities. When seeded at 2 × 106 cells/mL, L0, L1 and 
L2 cells expanded ~175-, 170- and 139-fold to yield 3.5 × 108, 3.4 × 108 and 2.8 × 108 cells/mL by day 12 (Fig. S3). When 
seeded at 5 × 105, L0, L1 and L2 cells expanded ~683-, 640- and 500-fold to yield 3.4 × 108, 3.2 × 108 and 2.5 × 108 cells/
mL by days 14 (Fig. S3). Majority of TICs expressed Nestin, SOX2 and Olig2, while very few of them expressed the 
differentiation markers Tuj1 and GFAP after the 7-day culturing (Figs 2E and S2C). Live/dead cell staining detected 
very few dead cells (Figs 2B and S2B) and this was confirmed with Annexin V and PI staining (Figs 2F and S2D). We 
did not see significant difference in terms of cell viability, cell growth rate, yield and TIC markers expression when TICs 
were cultured in AlgTubes with diameters in the range of 100 μm to 400 μm. In short, glioblastoma TICs from different 
patients could be efficiently expanded in the new culture technology.
Long-term culturing of glioblastoma TICs in AlgTubes. To assess whether the AlgTubes support 
long-term culturing of glioblastoma TICs, all the three lines (L0, L1 and L2) were continuously cultured for 10 
passages (e.g. about two months). Cells were passaged every 5 days. During the 10-passage culture, when seeded 
at 1.0 × 107 cells/mL, L0, L1 and L2 expanded ~23-, 19- and 12-fold per passage per 5 days, respectively, with cell 
viability >95% (Fig. 3A,B). We re-evaluated the cell growth kinetics at passage 10 to study if the long-term cul-
turing changed the cell growth rate or phenotype. When seeded at 1 × 107 cells/mL, L0, L1 and L2 expanded ~36-, 
32 and 29-fold, yielding 3.6 × 108, 3.2 × 108 and 2.9 × 108 cells/mL, respectively, by day 7 (Fig. 3D,E). Majority of 
TICs expressed Nestin, SOX2 and Olig2, while very few of them expressed the differentiation markers Tuj1 and 
GFAP (Figs 3F and S4B). The percentage of CD133+, CD15+ and CD44+ cells at passage 10 were very similar 
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to these of the starting materials (Figs 3G and S1,4C). Our qPCR data also showed there were no differences in 
Nestin, CD44, CD15 and CD133 mRNA expressions between passage 10 and passage 0 (Fig. S4D,E). These data 
indicate that there are no significant phenotypic changes during the long-term culturing.
To confirm the stem cell identity of TICs after the long-term culturing, we withdrawn the bFGF factors from the 
culturing medium to initiate spontaneous differentiation of TICs within the tubes. After two weeks, all three TICs 
generated Tuj1+ neurons and GFAP+ glial cells (Figs 4A and S5). The removal of bFGFs did not induce significant 
cell death (Fig. 4B). These cells also successfully formed tumors when transplanted into immune-deficiency mice. 
Majority of the cells in the tumor were HuNu+ human cells and large percentages of cells were Ki67+ proliferating 
cells. Histological analysis showed Tuj1+ neurons, GFAP+ glial cells and Nestin+ TICs in all tumors (Fig. 5).
Figure 1. Culturing glioblastoma tumor-Initiating cells (TICs) in alginate hydrogel tubes (AlgTubes). (A,B) 
Glioblastoma TICs were suspended and cultured in microscale alginate hydrogel tubes that were suspended 
in the cell culture medium in a culture vessel. The tubes protected cells from hydrodynamic stresses in the 
culture vessel and confined the cell mass less than 400 µm (in radial diameter) to ensure efficient mass transport. 
They also provided microspaces for cells to interact with each other and expand. Cell culture medium could 
efficiently diffuse through the alginate hydrogel shell. An illustration (A) and microscope picture (B) of an 
AlgTube. (C) To process AlgTubes, a cell and an alginate solution was pumped into the central channel and side 
channel of a micro-extruder, respectively, to form coaxial core-shell flows that were extruded through the nozzle 
of the micro-extruder into a CaCl2 buffer. The shell alginate flow was instantly crosslinked by the Ca2+ ions to 
form an alginate hydrogel tube. (D) In AlgTubes, individual cells first associated to form small cell clusters. 
Subsequently, cells proliferated and the small cell clusters expanded to form fibrous cell mass. Scale bar: 200 µm.
www.nature.com/scientificreports/
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Scalable culturing of glioblastoma TICs with AlgTubes in a bioreactor. A prototype bioreactor was 
developed for the scalable manufacturing of glioblastoma TICs using AlgTubes (Fig. 6). The bioreactor contains 
a cylindrical container and a plastic bellow bottle, which were separated by a nylon mesh. AlgTubes with cells 
Figure 2. Culturing glioblastoma TICs in AlgTubes at passage 1. (A) Microscopy images of glioblastoma TICs 
(L0) in AlgTubes on day 0, 5 and 7. (B) Live/dead staining of day 7 cells in AlgTubes. (C,D) The expansion fold 
and volumetric yield of TICs from day 3 to day 7. When seeded at 1 × 107 cells/mL, L0, L1 and L2 expanded 36-, 
34- and 28-fold, yielding 3.6 × 108, 3.4 × 108 and 2.8 × 108 cells/mL by day 7, respectively. (E) Immunostaining 
of the cultured TICs. Cells were released from AlgTubes on day 7 and plated on a Laminin-coated plate 
overnight before fixing and staining. Majority of L0 cells were Nestin+, SOX2+ and Olig2+. Few L0 cells were 
Tuj1+ and GFAP+. (F) Cell death was evaluated by Annexin V and PI staining after cultured in AlgTubes for 7 
days. Error bars represent the standard deviation (n = 3). Scale bar: (A,B) 400 µm, (E) 50 µm.
www.nature.com/scientificreports/
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Figure 3. Long-term culturing of glioblastoma TICs in AlgTubes. (A) When seeded at 1.0 × 107 cells/mL, L0, 
L1 and L2 expanded ~23-, 19- and 12-fold/passage/5 days, respectively, along a 10-passage culture with (B) cell 
viability was >95%. (C) Microscopy images of L0 cells on day 0, 1, 5 and 7 at passage 10. (D,E) The expansion 
fold and volumetric yield of TICs from day 3 to day 7 at passage 10. When seeded at 1 × 107 cells/mL, L0, L1 and 
L2 expanded 36-, 32- and 29-fold, yielding 3.6 × 108, 3.2 × 108 and 2.9 × 108 cells/mL by day 7, respectively. (F) 
Immunostaining of the cultured TICs. Cells were released from AlgTubes on day 7 at passage 10 and plated on 
a Laminin-coated plate overnight before fixing and staining. Majority of L0 were Nestin+, SOX2+ and Olig2+. 
Few L0 cells were Tuj1+ and GFAP+. (G) Flow cytometry analysis showed that 5.2% L0 cells were CD133+, 
21.2% L0 cells were CD15+ and 99.9% L0 cells were CD44+. Error bars represent the standard deviation 
(n = 3). Scale bar: (C) 200 µm; (F) 50 µm.
www.nature.com/scientificreports/
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were suspended in the cylindrical container and the medium was stored in the plastic bellow bottle that could be 
pressed by a mechanic stage to flow the medium into, or released to withdraw the medium from the container 
(Fig. 6A,B). A mechanic stage was used to press and release the bellow bottle. A controller that can be pro-
grammed for the pressing and releasing speed, as well as the duration of the interval between the pressing and 
releasing was used to control the mechanic stage (Fig. 6C). Glioblastoma TICs grew well in the bioreactor and 
yielded ~3.0 × 108 cells/mL (Fig. 6D). Majority of TICs expressed Nestin, SOX2 and Olig2, while very few of them 
expressed the differentiation markers Tuj1 and GFAP (Figs 6E and S6).
Comparing culturing glioblastoma TICs in AlgTubes, 2D culturing, static 3D and dynamic 3D 
suspension culturing. To show the superiority of AlgTubes for culturing glioblastoma TICs over current 
technologies, we directly compared expanding glioblastoma TICs (L0) in AlgTubes, 2D culturing, static 3D 
and dynamic 3D suspension culturing (Figs 7A–C and S7). For 2D culturing, 1 × 105 cells/well were seeded in 
Laminin-coated 6-well plate. Cells reached confluent by day 5. L0 cells expanded ~27-fold to generate ~2.7 × 106 
cells per well of the 6-well plate. For static 3D suspension culturing, in which cells were suspended in culture 
medium at 1 × 105 cells/mL without agitation, L0 cells formed aggregates with diameter in the range of 100 to 
350 µm by day 7 and expanded ~12-fold to yield ~1.2 × 106 cells/mL. In dynamic 3D suspension culture, in which 
Figure 4. In vitro differentiation of glioblastoma TICs. (A) After 10 passages in AlgTubes, L0, L1 and L2 were 
spontaneously differentiated in AlgTubes for 2 weeks. Fibrous cell masses were fixed for staining. All TICs could 
be differentiated into Tuj1+ neurons and GFAP+ glial cells. (B) After 10 passages in AlgTubes, L0, L1 and L2 
were cultured for 7 days after removing bFGF from the culture. Cell death was evaluated by Annexin V and PI 
staining for L0, L1 and L2. Scale bar: 100 µm.
www.nature.com/scientificreports/
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cells were suspended in culture medium at 1 × 105 cells/mL with agitation (~75 rotation per minute), L0 cells 
expanded ~20-fold to yield ~2 × 106 cells/mL. In AlgTubes, L0 cells expanded ~710-fold to yield ~3.55 × 108 cells/
mL by 14 days when seeded at 5 × 105 cells/mL. For all the cultures, majority of cells were Nestin+, SOX2+ and 
Olig2+. Few cells were Tuj1+ and GFAP+. In short, AlgTubes result in much higher expansion and volumetric 
yield than the current culture methods.
Discussion
Our results showed TICs expanded around 25-fold, yielding ~2.5 × 106 cells/well in 5 days in 2D culturing 
(Figs 7A,B and S7). In a typical drug screening, ~1 × 1010 glioblastoma TICs are needed to screen a library with 
1 × 106 compounds once. About seven hundreds of 6-well plates will be used to generate these cells. Maintaining 
these plates requires large incubator space, labor, time and cost. In addition, plate-to-plate and batch-to-batch 
variations are common in 2D culturing. Therefore, 2D culturing is generally considered not suitable for culturing 
large-scale cells28–30.
3D suspension culturing is considered promising for scaling up the cell production28–30. The neurosphere 
culture is commonly used for isolating and expanding glioblastoma TICs17,24–26. However, a significant problem 
with 3D suspension culturing is the uncontrolled cell agglomeration. Human cells usually have strong cell-cell 
interactions that make them aggregate38,39. Suspended cells tend to form large cell agglomerates (i.e., agglom-
eration), especially at high cell culture density. The agglomeration leads to inhomogeneity in cell aggregate size 
and is detrimental to cell culture28. For instance, the transport of nutrients, oxygen and growth factors to and the 
Figure 5. Xenotransplantation of glioblastoma TICs. After 10 passages in AlgTubes, TICs were transplanted 
subcutaneously to NOD-SCID mice. (A,E) Harvested tumors. (B,F) H&E staining of the tumor sections. (C,G) 
Large percentage of cells in the tumor tissue were human nuclear antigen (HuNu) positive human cells and were 
proliferating (Ki67+). (D,H) Nestin+ TICs, Tuj1+ neurons and GFAP+ glia cells were all found in the tumor 
tissue. Scale bar: 50 µm.
www.nature.com/scientificreports/
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metabolic waste from, cells located at the center of large cell agglomerates (e.g., >400 µm diameter) become insuf-
ficient, leading to slow cell growth, apoptosis and phenotype changes28,40. Our results showed about 1 × 106 TICs 
per milliliter of volume could be produced with 3D suspension culturing without agitation (Figs 7A,B and S7). 
With this yield, it will require about 10 liters culture volume to generate ~1 × 1010 glioblastoma TICs.
Agitation is generally applied to enhance the medium mixing and mass transport and reduce the cell agglom-
eration in 3D suspension culturing41. Our results showed TIC aggregates were much smaller and uniform under 
agitation (Fig. S7). However, agitation also generates complicated hydrodynamic conditions (e.g., the medium 
flow direction, velocity, shear force and chemical environment) that are spatially and temporally varied, resulting 
in locations with turbulence and critical stresses (e.g., near the vessel wall and impeller tip) that induce cell death 
and differentiation, leading to low cell viability, growth and yield in 3D suspension culturing27–30,42–46. Further, the 
hydrodynamic conditions are sensitive to many factors including the bioreactor design (e.g., impeller geometry, 
size and position, vessel geometry and size, positions of probes for pH, temperature and oxygen), medium viscos-
ity and agitation rate28,42. They are currently not well understood and they are hard to control28,42,45,46. Moreover, 
how cells respond to the hydrodynamic conditions is not well known and is hard to study28,45,46. These knowledge 
gaps result in culture inconsistency and difficulty in scaling up cell production. We demonstrated that glioblas-
toma TICs expanded ~20 fold, yielding ~2 × 106 cells/mL in dynamic 3D suspension culturing (Figs 7A,B and S7). 
With this yield, it will require about 5 liters of culturing, a culture volume that has not been demonstrated for 
TICs, to generate ~1 × 1010 glioblastoma TICs.
We propose that culturing conditions mimicking the in vivo 3D cell microenvironment that have no hydro-
dynamic stresses and uncontrolled cell agglomerations can significantly improve the cell culture efficiency. 
Accordingly, we designed the AlgTubes cell culture system for scalable culturing high quality and high quantity 
glioblastoma TICs. Unlike the traditional hydrogel-based cell culturing methods, in which cells are encapsulated 
and grown in hydrogel scaffolds18,47,48, in AlgTubes, cells are cultured in the free microspaces created by hydrogel 
tubes. The microspaces allow cells to efficiently interact with each other and expand, leading to high volumetric 
yield. The size of cell masses in AlgTubes is monodispersed and can be precisely controlled, which can signifi-
cantly improve the culture homogeneity and efficiency. Cells in the AlgTubes are protected from the hydrody-
namic stresses by the alginate shell, which can significantly reduce cell death.
The conceptual and technical innovations of AlgTubes lead to high culture efficiency. Primary glioblastoma TICs 
from different donors could be efficiently cultured in AlgTubes with high growth rate (~700-fold expansion/14 
days) and high volumetric yield (~3.0 × 108 cells/mL) (Figs 2 and S3). With this yield, it will take about 30 milliliters 
Figure 6. A prototype bioreactor for scalable TICs production. (A) The bioreactor contains a cylindrical container 
and a plastic bellow bottle, which are separated by a nylon mesh. AlgTubes with TICs are suspended in the 
cylindrical container and the medium is stored in the plastic bellow bottle that can be pressed to flow the medium 
into, or released to withdraw the medium from the container. (B,C) Images of the bioreactor. The mechanic stage 
is used to press and release the bellow bottle. The controller can be programmed for the pressing and releasing 
speed, as well as the duration of the interval between the pressing and releasing. (D) Glioblastoma TICs harvested 
from the bioreactor on day 10. TICs grew well and yielded ~3.0 × 108 cells/mL. (E) Immunostaining of the cultured 
TICs. Majority of L0 were Nestin+, SOX2+ and Olig2+. Few L0 cells were Tuj1+ and GFAP+. Scale bar: 50 µm.
www.nature.com/scientificreports/
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of AlgTubes to generate ~1 × 1010 glioblastoma TICs. After long term (~50 days, 10 passages) culture in AlgTubes, 
these cells still expressed the TIC markers Nestin, Sox2, CD44, Olig2, CD133 and CD15. The percentage of positive 
cells to these markers were not altered by the long-term culturing. It should be noted that using surface makers, such 
as CD133, to define glioblastoma TICs is still controversial11,14–16. For instance, the %CD133+ cells ranged from 
~1% to ~96% and %CD15+ cells ranged from ~1% to ~48% in brain TICs from different patients2. Some other 
studies have questioned the utility of using CD133 as a marker for tumor-initiating cells11,14–16,49–52. Thus, we use 
three phenotype-based criteria to define glioblastoma TICs in this paper: (1) they can self-renew; (2) they can be 
differentiated into neural and glial cells; and (3) they can initiate tumors in in vivo. Our results showed TICs cultured 
for long-term in AlgTubes retained their capability to differentiate into neurons and glia cells (Figs 3, 4 and S4,5) or 
re-initiate tumors in vivo (Fig. 5). Additionally, AlgTubes-based bioreactors could be readily built for the scalable 
production of TICs (Fig. 6). Our comparative studies showed the AlgTubes offered significant advantages over the 
2D, static 3D and dynamic 3D suspension culturing in terms of cell growth rate and yield (Fig. 7).
To our best knowledge, this is the first that utilizes alginate hydrogel tubes for successful TIC expansion. The 
AlgTubes will be of broad interest to individual laboratories, institutions and biotechnology companies working 
on developing new cancer therapies. AlgTubes can be a valuable tool for laboratories to maintain TICs. Due to its 
high volumetric yield and scalability, AlgTubes are particularly attractive for large-scale TIC production. A sim-
ple comparative calculation of producing ~1 × 1012 glioblastoma TICs from ~1 × 107 seeds with 3D suspension 
culturing (e.g. the stirred-tank bioreactors) and AlgTubes shows the significant impact of AlgTubes’ high cell 
expansion per passage and volumetric yield (Fig. 7D). For the calculation, we assumed 20-fold expansion per 7 
days per passage for stirred-tank bioreactors and 700-fold expansion per 14 days per passage for AlgTubes with 
the seeding density of 1 × 105 cells/mL and 5 × 105 cells/mL, respectively and a passaging efficiency (i.e., % of cells 
remaining viable after one passaging) of 80% for both. These assumptions are based on our research data. The 
production requires ~874 liters of total culture volume, 4 passaging operations and 28 days with stirred-tank bio-
reactors, which is technically and economically challenging (Fig. 7D). The production can be done with 4.49 liters 
of AlgTubes in 28 days and 2 passaging (Fig. 7D). The reductions in culture volume, culture time and passaging 
make the production technically feasible and also lead to enormous cuts in overall production cost.
Figure 7. Comparing culturing glioblastoma TICs in AlgTubes, 2D culturing, static 3D and dynamic 3D 
suspension culturing. Glioblastoma TICs (L0) were seeded at 1 × 105 cells/well (of 6-well plate) and cultured 
for 7 days in 2D culturing; seeded at 1 × 105 cells/mL and cultured for 9 days in static 3D and dynamic 3D 
suspension; seeded at 5 × 105 cells/mL and cultured for 14 days in AlgTubes. (A) The expansion fold, (B) 
volumetric yield and (C) % cell Nestin+ cells in the culture were quantified. (D) A comparative calculation 
of producing 1.3 × 1012 glioblastoma TICs. In a bioprocess using dynamic 3D suspension culturing (e.g. with 
stirred tank bioreactor), 1.3 × 1012 TICs are generated through series expansions of 2.0 × 107 cell seeds with 
4 passaging operations in 28 days. The total culture volume is ~874 liters. In a bioprocess using AlgTubes, 
1.3 × 1012 TICs are generated from 4.0 × 106 seeds with 2 passaging operation in 28 days. Total of 4.49 liters 
AlgTubes are needed. #P < 0.05. Data are presented as mean ± SD of three replicates (n = 3). Note for 2D 
culturing, the unit for cell density in (B) is cells/well (of 6-well plate).
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The AlgTubes will also significantly advance the precision or personalized medicine. There are large varia-
tions between tumors or patients in terms of the genetics, epigenetics, cellular compositions and drug response 
or resistance53. The conventional method of using one treatment or drug (e.g. chemotherapy plus radiotherapy) 
to treat all patients has been proven to be of limited success. A better way is the precision or personalized med-
icine54,55. With this approach, tumor cells from each patient can be expanded in vitro and used to screen or test 
the existing drugs or their combination to find the best treatment for each patient. However, the widespread use 
of this approach highly relies on technologies that can efficiently and cost-effectively culture TICs for thousands 
of individuals. With AlgTubes, cells required for one patient (e.g. ~1010 cells) can be produced with about 30 mL 
alginate hydrogel tubes that can be contained in a closed 50 mL conical tube. Cells for many patients can be auto-
matically produced with corresponding numbers of 50 mL tubes in parallel.
Conclusion
In conclusion, we developed a new method for culturing glioblastoma TICs with high efficiency. It is simple, 
scalable and cost-effective. We believe the technology is a valuable tool for developing therapies targeted to TICs.
Materials and Methods
Materials. Cell culture reagents and their supplies: NeurocultTM NS-A Proliferation kit (Stem cell technolo-
gies); Laminin (Invitrogen); Trypsin-EDTA (Invitrogen); Heparin and Trypsin inhibitor (Sigma); EGF and FGF 
(R&D). Syringe pump (New Era Pump System, Inc.); Disposable syringes (Henke sass wolf); Sodium Hyaluronate 
(Lifecore Biomedical); Sodium alginate (80~120 cp, Wako Chemicals); Calcium chloride (Acros Organics); 
Sodium Chloride (Fisher scientific). Mechanical stage and controller (CESCO); Bellows bottles (Spectrum 
Chemical Mfg. Corp.). Antibodies and their supplies: Tuj1 (1:10,000; Sigma); Nestin (1:200; Millipore); Ki-67 
(1:500; Invitrogen); anti-glial fibrillary acidic protein (1:500; Dako); SOX2 (10 µg/mL; R&D system); Olig2 
(20 µg/mL; Novus Biologicals); Calcein AM viability dye (eBiosicence); Ethidium homodimer I (Biotium); DAPI 
(Sigma). Trypan blue solution was obtained from Sigma-Aldrich. TRIzol (Ambion); Maxima first strand cDNA 
synthesis Kit (Thermo Fisher Scientific); Power SYBR Green Master Mix (Applied biosystems).
Isolating primary TICs. All experiments were conducted in accordance with the national regulations. All 
experiments were approved by the Institutional Review Board (IRB) at University of Florida. All patients gave 
their informed consent before the experiments. Fresh brain tumor samples were acquired at the time of surgical 
excision. To establish these cell lines, the tumor samples were dissociated into single cells with 0.5% trypsin and 
then cultured in NeurocultTM medium supplemented with bFGF, EGF and heparin7.
2D adherent culturing. For 2D adherent expansion, glioblastoma TICs were cultured in 6-well plates which 
were pre-coated with 10 μg/mL Laminin at 37 °C for 3 hours with NeurocultTM medium supplemented with 10 ng/
ml bFGF, 20 ng/ml EGF and 2 μg/mL heparin. The medium was changed daily and cells were passaged every 5 
days. Briefly, cells were treated with 0.05% trypsin for 2–3 min at 37 °C and dissociated into single cells with a 
pipette. Then an equal volume of trypsin inhibitor was added to inactivate the trypsin. 1 × 105 cells were usually 
passaged for each well of 6-well plate.
3D neurosphere culturing. Glioblastoma TICs neurospheres were treated with 0.05% trypsin at 37 °C for 
5 min and dissociated into single cells with pipettes. Equal volume trypsin inhibitors were then added to inac-
tivate the trypsin. 1 × 105 cells/mL cells were seeded cells in non-treated T-25 Flask with NeurocultTM medium 
supplemented with 10 ng/ml bFGF, 20 ng/ml EGF and 2 µg/ml heparin. The medium was changed daily and cells 
were passaged every 5 days.
3D suspension culturing in shaking plates. Glioblastoma TICs were suspended in low attached 6-well 
plate with NeurocultTM medium supplemented with 10 ng/ml bFGF, 20 ng/ml EGF and 2 μg/mL heparin. The 
plates were shaken at 75 rpm. The medium was changed daily and cells were passaged every 5 days. For passage, 
TICs cells were collected via centrifuging at 200 g for 3 minutes and treated with 0.05% trypsin at 37 °C for 5 min 
before dissociating into single cells with pipettes. Equal volume trypsin inhibitors were then added to inactivate 
the trypsin.
Processing AlgTubes. A micro-extruder was fabricated to process AlgTubes. 2% Hyaluronic acid (HA) 
solution containing single glioblastoma TICs is pumped into the central channel and 1.5% alginate solution in 
145 mM NaCl is pumped into the side channel of the micro-extruder. The corresponding coaxial core-shell flow 
is extruded into a 100 mM Ca2+ buffer, which instantly crosslinks the alginates solution to form a hydrogel shell 
to make AlgTubes. Subsequently, cells laden AlgTubes were transferred to 6-well plate for culturing with the 
medium.
Culturing glioblastoma TICs in AlgTubes. For a typical culture, 20 µL of glioblastoma TICs in the 
AlgTubes were suspended in 2 mL NeurocultTM medium supplemented with 10 ng/ml bFGF, 20 ng/ml EGF and 
2 µg/mL heparin in a 6-well plate and cultured at 37 °C with 5% CO2 and 21% O2. The medium was changed daily. 
To passage cells, the AlgTubes were dissolved with 0.5 mM EDTA for 5 minutes. The released cell mass was col-
lected and treated with 0.05% trypsin at 37 °C for 5 minutes and dissociated into single cells with a pipette. Equal 
volume trypsin inhibitors were then added to inactivate the trypsin. Cell viability was qualitatively evaluated 
with live/dead cell staining according to the product manual (life technology). To quantify the viability, cells were 
stained with trypan blue and % of live cells were measured with a cell counter (TC20™, Bio-Rad).
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In vitro differentiation. For 2D differentiation, glioblastoma TICs cell masses were plated onto Laminin 
coated plates and cultured for two weeks in NeurocultTM medium without bFGF, EGF or heparin. For 3D differ-
entiation in the AlgTubes, glioblastoma TICs cell masses in AlgTubes were cultured for two weeks in NeurocultTM 
medium without bFGF, EGF or heparin.
Xenotransplantation. All animal protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Nebraska-Lincoln. All experimental procedures involving animals were carried 
out in accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of 
Nebraska-Lincoln. Glioblastoma TICs (~2 × 106) were suspended in 25 µL PBS+ 25 µL Matrigel and injected 
subcutaneously at the back of the neck of the NOD-SCID mice. The tumors were harvested when sizes reached 
about 1.0 cm within 2 months. After fixed with 4% PFA for 48 hours, the tumors were cut into two halves. The first 
half was used for hematoxylin and eosin staining. Briefly, after sequentially dehydrated with 70%, 95% and 100% 
ethanol, the samples were embedded in paraffin and cut into 10 µm thick sections before staining. The second half 
was employed for immunostaining. Briefly, the samples were soaked in 20% sucrose for 7 days before embedded 
in OCT compounds and frozen. The samples were then cryosectioned for 10 µm thick sections before staining.
Staining and imaging. To stain 2D surfaces glioblastoma TICs, cells were fixed with 4% paraformaldehyde 
(PFA) for 15 minutes and permeabilized with 0.25% Triton X-100 for 10 min and blocked with 5% goat serum for 
1 hour. The samples were then incubated with primary antibodies at room temperature for 2 hours. After washed 
with PBS for 3 times, secondary antibodies in 2% BSA were added and incubated for another 1 hour before 
imaging. To stain 3D fibrous glioblastoma TICs in AlgTubes, cells were fixed with 4% PFA at room temperature 
for 1 hour, then incubated with PBS+ 0.25% Triton X-100+ 5% goat serum+ primary antibodies (Nestin, 1:200, 
Millipore; SOX2, 10 µg/mL, R&D system; Olig2, 20 µg/mL, Novus Biologicals; Tuj1, 1:10,000, Sigma; anti-glial 
fibrillary acidic protein, 1:500, Dako; Ki-67, 1:500, Invitrogen) at 4 °C for 2–3 days. After extensive washing, 
secondary antibodies (Alexa 488 Donkey anti-mouse, 1:500; Alexa 594 Donkey anti-rabbit, 1:500) in 2% BSA 
was added and incubated at 4 °C for 1 day. Cells were washed with PBS before imaging with NIKON A1 Confocal 
Microscopy. LIVE/DEAD® cell viability staining was utilized to assess live and dead cells according to the product 
manual.
Flow cytometry. We used the following antibodies: CD44-PE-Cy5 (1:100) (eBioscience), CD15-APC (1:5) 
(BD), CD133/2-PE (1:50) (Miltenyi Biotec). Annexin V-FITC Apoptosis Detection Kit was obtained from eBio-
science. Staining was quantified by flow cytometry (Cytek DxP10).
Quantitative real time polymerase chain reaction (qRT-PCR). Total RNA was extracted from the 
harvested cells using TRIzol reagent. cDNA was synthesized using Maxima first strand cDNA synthesis kit 
according to the manufacturer’s instructions. Quantitative real time polymerase chain reaction was performed 
using Power SYBR Green Master Mix in an Eppendorf MasterCycler RealPlex4 (ThermoFisher Scientific). 
Experiments were performed in triplicate. The 2−∆∆Ct method was employed to calculate the specific gene fold 
change of P10/P0, where ∆∆Ct = (Cttarget P10-CtGAPDH P10) - (Cttarget P0-CtGAPDH P0).
Statistical analysis. The data are presented as the mean ± S.D. We employed an unpaired t-test to com-
pare two groups and one-way ANOVA to compare more than two groups. P < 0.05 was considered statistically 
significant.
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